Leader of several oncology drug approvals to head BioAtla’s CABs clinical development programs focused on immuno-oncology
SAN DIEGO, CA – May 9, 2017 – BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Yong Ben, M.D., as chief medical officer. Dr. Ben, an experienced biotechnology drug developer in oncology, joins the Company from AstraZeneca, where he was most recently Global Clinical Lead, Immuno-Oncology. His clinical leadership in pharmaceutical and biotechnology companies led to several oncology drug approvals including, for AstraZeneca, the most recent approval of a PD-L1 antibody, durvalumab (Imfinzi), for the treatment of urothelial cancer, ixazomib (Ninlaro) in multiple myeloma for Millennium/Takeda, axitinib (Inlyta) in renal cancer for Pfizer, and oncolytic virus H101 in head and neck cancer for SunwayBio.
"Dr. Ben's experience and proven capabilities in leading the clinical development of innovative oncology products over a range of indications greatly enhances BioAtla's ability to design, implement, and execute clinical programs evolving from our CAB platform" said Jay M. Short, Ph.D., chairman, president and chief executive officer of BioAtla.
About Dr. Ben
Dr. Ben joins BioAtla with over 20 years of industry and academic experience in oncology. During his 13 years of increasing responsibility in biotechnology and pharmaceutical companies, he has led wide-spectrum clinical development efforts from start to finish covering from phase 1 to phase 3 clinical trials, from strategy planning to study execution and BLA/NDA submissions. Prior to his career at AstraZeneca, Dr. Ben was Medical Director, Oncology Clinical Research at Millennium Pharmaceuticals where, in addition to leading the pivotal global phase 3 study for ixazomib in refractory/relapsed multiple myeloma, he was clinical lead in the orteronel and alisertib programs. Prior to then, Dr. Ben was Lead Clinician/Global Medical Monitor, Clinical Development for the Pfizer Oncology Business Unit and earlier was Project Manager, Asia Research & Development for Pfizer Global Research & Development. Dr. Ben began his career in industry with Shanghai Sunway Biotech Co., the world leader in the field of oncolytic virus. Dr. Ben started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center Research Institute. Dr. Ben received his medical degree from Norman Bethune Medical University and his MBA from University of California, San Diego.